FRIDAY, Jan. 6, 2023 (HealthDay News) — The U.S. Food and Drug Administration on Friday approved a second Alzheimer’s drug, lecanemab, despite reports of rare brain bleeds linked to use of the drug in some patients. However, the FDA pointed to the drug’s benefits, as well. “Alzheimer’s disease immeasurably incapacitatesContinue Reading

THURSDAY, Jan. 5, 2023 (HealthDay News) — Lecanemab: It’s an experimental medication that’s been shown in trials to slow cognitive decline in people with Alzheimer’s disease. It’s also up for accelerated approval by the U.S. Food and Drug Administration, with a decision expected by Jan. 6. However, the drug hasContinue Reading

TUESDAY, Jan. 3, 2023 (HealthDay News) — It’s safe for kids to take the COVID-19 vaccine after they’ve suffered a rare complication from a prior COVID infection, a U.S. National Institutes of Health-supported study has concluded. Multisystem inflammatory syndrome in children (MIS-C) affects about 1 in every 3,000 to 4,000Continue Reading

THURSDAY, Dec. 22, 2022 (HealthDay News) — Researchers are studying whether deep brain stimulation could help people with Alzheimer’s hold on to their memory longer, and now a new finding may help refine the approach. Deep brain stimulation (DBS) is an established treatment for several medical conditions, including epilepsy, Parkinson’sContinue Reading